SG11202106605VA - Compounds that participate in cooperative binding and uses thereof - Google Patents
Compounds that participate in cooperative binding and uses thereofInfo
- Publication number
- SG11202106605VA SG11202106605VA SG11202106605VA SG11202106605VA SG11202106605VA SG 11202106605V A SG11202106605V A SG 11202106605VA SG 11202106605V A SG11202106605V A SG 11202106605VA SG 11202106605V A SG11202106605V A SG 11202106605VA SG 11202106605V A SG11202106605V A SG 11202106605VA
- Authority
- SG
- Singapore
- Prior art keywords
- participate
- compounds
- cooperative binding
- cooperative
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783816P | 2018-12-21 | 2018-12-21 | |
| US201962894493P | 2019-08-30 | 2019-08-30 | |
| US201962930489P | 2019-11-04 | 2019-11-04 | |
| PCT/US2019/068100 WO2020132597A1 (en) | 2018-12-21 | 2019-12-20 | Compounds that participate in cooperative binding and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106605VA true SG11202106605VA (en) | 2021-07-29 |
Family
ID=71099011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106605VA SG11202106605VA (en) | 2018-12-21 | 2019-12-20 | Compounds that participate in cooperative binding and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200197391A1 (en) |
| EP (1) | EP3897644A4 (en) |
| JP (1) | JP2022520154A (en) |
| KR (1) | KR20210116479A (en) |
| CN (1) | CN113498342A (en) |
| AU (1) | AU2019401466A1 (en) |
| BR (1) | BR112021012057A2 (en) |
| CA (1) | CA3123869A1 (en) |
| IL (1) | IL284210A (en) |
| MX (1) | MX2021007468A (en) |
| SA (1) | SA521422304B1 (en) |
| SG (1) | SG11202106605VA (en) |
| TW (1) | TW202039509A (en) |
| WO (1) | WO2020132597A1 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201900157RA (en) | 2016-07-12 | 2019-02-27 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| MX2019008696A (en) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Pyridine compounds as allosteric shp2 inhibitors. |
| CN117327075A (en) | 2017-01-23 | 2024-01-02 | 锐新医药公司 | Bicyclic compounds as allosteric SHP2 inhibitors |
| WO2019075265A1 (en) | 2017-10-12 | 2019-04-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| BR112020009757A2 (en) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | polycyclic compounds as allosteric inhibitors of shp2 |
| CA3159561A1 (en) * | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2022553859A (en) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | RAS inhibitor |
| US20210322405A1 (en) * | 2020-04-15 | 2021-10-21 | Washington University | Compositions and methods for treating cancer |
| BR112022025550A2 (en) | 2020-06-18 | 2023-03-07 | Revolution Medicines Inc | METHODS TO DELAY, PREVENT, AND TREAT ACQUIRED RESISTANCE TO RAS INHIBITORS |
| MX2023002248A (en) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations. |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| US20240182487A1 (en) * | 2020-12-17 | 2024-06-06 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
| AR125787A1 (en) * | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
| PE20240088A1 (en) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | RAS INHIBITORS |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| IL308771A (en) | 2021-05-25 | 2024-01-01 | Revolution Medicines Inc | Methods for inhibiting ras |
| JP2024521788A (en) * | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス， インコーポレイテッド | Combination therapy |
| WO2023015559A1 (en) * | 2021-08-13 | 2023-02-16 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocycle compounds as inhibitors of ras |
| AR126854A1 (en) | 2021-08-27 | 2023-11-22 | Hoffmann La Roche | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| TW202340214A (en) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023208005A1 (en) * | 2022-04-25 | 2023-11-02 | Hansoh Bio Llc | Cyclic compounds, preparation methods and medicinal uses thereof |
| WO2023232776A1 (en) | 2022-06-01 | 2023-12-07 | F. Hoffmann-La Roche Ag | Haloindole macrocyclic compounds for the treatment of cancer |
| WO2023240263A1 (en) * | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024060966A1 (en) * | 2022-09-19 | 2024-03-28 | 杭州阿诺生物医药科技有限公司 | Pan-kras inhibitor compound |
| WO2024067857A1 (en) * | 2022-09-29 | 2024-04-04 | 南京明德新药研发有限公司 | Macrocyclic derivative and use thereof |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN116284045A (en) * | 2023-05-18 | 2023-06-23 | 西南交通大学 | Chiral indole unit substituted tetrahydroisoquinoline compound and synthesis method thereof |
| CN116570599B (en) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Application of VS6766 in combination with LY3009120 and pharmaceutical composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601852B2 (en) * | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
| ES2541853T3 (en) * | 2010-02-09 | 2015-07-27 | Neurovive Pharmaceutical Ab | Sangliferin based compounds |
| KR101953210B1 (en) * | 2011-05-19 | 2019-02-28 | 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ | Macrocyclic Compounds as Protein Kinase Inhibitors |
| AR091279A1 (en) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE |
-
2019
- 2019-12-20 EP EP19901393.9A patent/EP3897644A4/en active Pending
- 2019-12-20 MX MX2021007468A patent/MX2021007468A/en unknown
- 2019-12-20 TW TW108146857A patent/TW202039509A/en unknown
- 2019-12-20 CN CN201980092760.0A patent/CN113498342A/en active Pending
- 2019-12-20 BR BR112021012057-2A patent/BR112021012057A2/en unknown
- 2019-12-20 US US16/723,438 patent/US20200197391A1/en not_active Abandoned
- 2019-12-20 WO PCT/US2019/068100 patent/WO2020132597A1/en active Application Filing
- 2019-12-20 SG SG11202106605VA patent/SG11202106605VA/en unknown
- 2019-12-20 JP JP2021535755A patent/JP2022520154A/en active Pending
- 2019-12-20 KR KR1020217022312A patent/KR20210116479A/en unknown
- 2019-12-20 CA CA3123869A patent/CA3123869A1/en active Pending
- 2019-12-20 AU AU2019401466A patent/AU2019401466A1/en active Pending
-
2021
- 2021-06-17 SA SA521422304A patent/SA521422304B1/en unknown
- 2021-06-20 IL IL284210A patent/IL284210A/en unknown
-
2023
- 2023-03-16 US US18/184,766 patent/US20240139185A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3897644A4 (en) | 2022-09-07 |
| AU2019401466A1 (en) | 2021-07-01 |
| EP3897644A1 (en) | 2021-10-27 |
| CN113498342A (en) | 2021-10-12 |
| KR20210116479A (en) | 2021-09-27 |
| US20200197391A1 (en) | 2020-06-25 |
| WO2020132597A1 (en) | 2020-06-25 |
| BR112021012057A2 (en) | 2021-10-19 |
| US20240139185A1 (en) | 2024-05-02 |
| MX2021007468A (en) | 2021-08-05 |
| IL284210A (en) | 2021-08-31 |
| SA521422304B1 (en) | 2023-12-21 |
| TW202039509A (en) | 2020-11-01 |
| CA3123869A1 (en) | 2020-06-25 |
| JP2022520154A (en) | 2022-03-29 |
| WO2020132597A8 (en) | 2020-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284210A (en) | Compounds that participate in cooperative binding and uses thereof | |
| EP3606492A4 (en) | Compounds that participate in cooperative binding and uses thereof | |
| EP3247378A4 (en) | Compounds that participate in cooperative binding and uses thereof | |
| IL272524A (en) | Clec9a binding agents and use thereof | |
| SG11202100931QA (en) | Muscle-targeting complexes and uses thereof | |
| IL262241A (en) | Trispecific and/or trivalent binding proteins | |
| EP3247377A4 (en) | Compounds that participate in cooperative binding and uses thereof | |
| GB201805963D0 (en) | PD-L1 Binding Affirmers and Uses Related Thereto | |
| IL277551A (en) | Trispecific binding molecules against caners and uses thereof | |
| HK1245287A1 (en) | IL13RAα2 BINDING AGENTS AND USE THEREOF IN CANCER TREATMENT | |
| ZA201808160B (en) | Bispecific binding proteins and uses thereof | |
| IL272064A (en) | Binding proteins 1 | |
| IL280526A (en) | Muscle-targeting complexes and uses thereof in treating muscle atrophy | |
| IL276497A (en) | Fibroblast binding agents and use thereof | |
| IL291007A (en) | Cd8 binding agents and uses thereof | |
| IL266516B (en) | Antibody binding specifically to cd66c and use thereof | |
| IL284053A (en) | Novel compounds and their use in therapy | |
| ZA202006103B (en) | Trispecific and/or trivalent binding proteins | |
| IL277158A (en) | Compounds and uses thereof to treat tumors in a subject | |
| PL3430913T3 (en) | Composition for binding mycotoxins and its use | |
| PL3067402T3 (en) | Binder composition and use of same in wooden boards | |
| IL267565A (en) | Binding polypeptides and methods of making the same | |
| HK1255409A1 (en) | Antibody binding agents that bind acinetobacter and uses thereof | |
| GB201617935D0 (en) | Binding compound and uses thereof | |
| GB201803519D0 (en) | Improvements in frying technology |